TTNP on NASDAQ
Logo: The logo is from the following website: http://www.titanpharm.com/ http://purecommunicationsinc.com/clients/, Non-free logo, via Wikipedia4
American pharmaceutical company
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system ("CNS") disorders.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 18, 2026.
Compare with Abpro Holdings, Inc., aTyr Pharma or WINDTREE THERAPEUTICS INC /DE/, or pick any stock.
See how the biggest companies compare on our leaderboards
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system ("CNS") disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.3
From the company’s reports to the SEC. Every number links to the filing it came from.
Out of $184.0K in revenue.7 The company lost money this year.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenue | $6.6M8 | $2.6M9 | $4.8M10 | $1.5M11 | $557.0K12 | $184.0K7 |
| Cost of revenue | $538.0K13 | $09 | $472.0K10 | $199.0K11 | ||
| Research and development | $7.5M13 | $5.1M9 | $5.9M10 | $5.7M11 | $4.8M12 | $1.9M7 |
| Selling, general and admin | $6.9M13 | $11.9M13 | ||||
| Operating income | -$8.3M13 | -$7.9M9 | -$7.4M10 | -$9.4M11 | -$10.2M12 | -$7.3M7 |
| Income tax | $013 | $09 | $010 | $010 | -$4.0K12 | $1.0K7 |
| Net income | -$9.0M13 | -$16.5M9 | -$18.2M10 | -$8.8M11 | -$10.2M12 | -$5.6M7 |
| Earnings per share | -$1.6413 | -$0.7213 | -$15.1912 | -$7.417 | ||
| Earnings per share (diluted) | -$1.6613 | -$0.7213 | -$15.1912 | -$7.417 |
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Cash | $9.3M13 | $5.2M9 | $5.4M10 | $6.0M11 | $2.9M12 | $6.8M7 |
| Current assets | $13.3M13 | $8.3M9 | $7.3M10 | $7.2M11 | $3.6M12 | $8.0M7 |
| Total assets | $14.1M13 | $9.5M9 | $8.1M10 | $8.0M11 | $4.1M12 | $8.1M7 |
| Current liabilities | $3.5M13 | $3.6M9 | $4.2M10 | $2.7M11 | $2.6M12 | $1.4M7 |
| Long-term debt | $3.8M13 | $4.0M9 | $332.0K10 | $010 | ||
| Total liabilities | $7.3M13 | $8.1M9 | $4.6M10 | $2.9M11 | $2.7M12 | $1.4M7 |
| Shareholders’ equity | $6.8M9 | $1.4M10 | $3.5M11 | $5.1M12 | $1.4M7 | $6.6M7 |
| Shares outstanding | 13.0M shares13 | 1.9M shares9 | 7.1M shares10 | 9.9M shares11 | 750.8K shares12 | 781.5K shares7 |
The company was founded in 1992 and is headquartered in San Francisco, California.
In August 2022, David Lazar was appointed chairman and CEO. He succeeded Marc Rubin, who had held the position since October 2007.
In 2024, the company entered into a merger agreement and became a wholly owned subsidiary of BSKE Ltd.
From Wikipedia’s article on Titan Pharmaceuticals, shared under CC BY-SA 4.0.6
Who has led Titan Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.
182 filings to the SEC since October 2021: 4 annual reports, 12 quarterly reports, 57 major events, 40 insider forms, 13 large holders, 1 private raises, 55 other. The latest 20:
The 182 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 13 such filings since October 2021, the latest 10:
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Private offerings the company reported to the SEC on Form D.
The numbers on this page point here. Each one links to the record it came from.
